Aclaris Therapeutics Company Profile (NASDAQ:ACRS)

About Aclaris Therapeutics (NASDAQ:ACRS)

Aclaris Therapeutics logoAclaris Therapeutics, Inc. is a United States-based clinical-stage specialty pharmaceutical company. The Company is focused on identifying, developing and commercializing drugs to address the needs in dermatology. Its lead drug candidate, A-101 Topical Solution, is a hydrogen peroxide topical solution that the Company is developing as a prescription treatment for seborrheic keratosis (SK). It has completed approximately three Phase II clinical trials of A-101. It has initiated over two multi-center, double blind Phase III clinical trials and an open label Phase III clinical trial of A-101 in patients with SK. It also intends to develop A-101 as a prescription treatment for common warts, also known as verruca vulgaris, and A-102, a gel dosage form of hydrogen peroxide, as a prescription treatment for SK and common warts. It has initiated a Phase II clinical trial to evaluate A-101 for the treatment of common warts.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology
  • Sub-Industry: N/A
  • Symbol: NASDAQ:ACRS
  • CUSIP: N/A
  • Web: www.aclaristx.com
Capitalization:
  • Market Cap: $663.25 million
  • Outstanding Shares: 26,733,000
Average Prices:
  • 50 Day Moving Avg: $28.07
  • 200 Day Moving Avg: $28.32
  • 52 Week Range: $17.10 - $33.25
P/E:
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -8.19
  • P/E Growth: -0.11
Sales & Book Value:
  • Annual Revenue: N/A
  • Price / Sales: N/A
  • Book Value: $6.14 per share
  • Price / Book: 4.04
Profitability:
  • EBIDTA: ($47,580,000.00)
  • Return on Equity: -47.62%
  • Return on Assets: -45.47%
Debt:
  • Current Ratio: 18.65%
  • Quick Ratio: 18.65%
Misc:
  • Average Volume: 268,475 shs.
  • Beta: 2.19
  • Short Ratio: 6.9
 

Frequently Asked Questions for Aclaris Therapeutics (NASDAQ:ACRS)

What is Aclaris Therapeutics' stock symbol?

Aclaris Therapeutics trades on the NASDAQ under the ticker symbol "ACRS."

How were Aclaris Therapeutics' earnings last quarter?

Aclaris Therapeutics Inc (NASDAQ:ACRS) released its quarterly earnings data on Tuesday, May, 9th. The company reported ($0.48) EPS for the quarter, beating the consensus estimate of ($0.54) by $0.06. View Aclaris Therapeutics' Earnings History.

Where is Aclaris Therapeutics' stock going? Where will Aclaris Therapeutics' stock price be in 2017?

4 equities research analysts have issued 1-year target prices for Aclaris Therapeutics' stock. Their forecasts range from $34.00 to $40.00. On average, they expect Aclaris Therapeutics' stock price to reach $36.67 in the next year. View Analyst Ratings for Aclaris Therapeutics.

What are analysts saying about Aclaris Therapeutics stock?

Here are some recent quotes from research analysts about Aclaris Therapeutics stock:

  • 1. According to Zacks Investment Research, "Aclaris Therapeutics, Inc. is a specialty pharmaceutical company. The Company is focused on identifying, developing and commercializing drugs to met needs in dermatology. Its drug candidate consists of A-101, a high-concentration hydrogen peroxide topical solution which is being developed as a prescription treatment for seborrheic keratosis a common non-malignant skin tumor and A-102, a proprietary topical gel dosage form of hydrogen peroxide for the treatment of SK and common warts which are in different clinical trial. Aclaris Therapeutics, Inc. is headquartered in Malvern, Pennsylvania. " (5/12/2017)
  • 2. Jefferies Group LLC analysts commented, "ACRS reported a narrower Q4 loss of $11.5M (vs $14.5M JEF) due to lower than projected R&D spend post the SK Ph3 trials. Attention now turns to three new clinical trials (A-101 Phase 2b in common warts and two JAK Ph 2s in alopecia areata) as we wait for an FDA decision on A-101 in SKs in early '18. We continue to forecast peak sales approaching $500M for the drug/device combo and think ACRS fits our M&A thesis." (3/16/2017)
  • 3. Guggenheim analysts commented, "We are raising our PT from $35 to $40 post 4Q16. We arrive at our PT by using a DCF analysis. Post the quarter, we continue to believe that upwards earnings revisions to levels not yet reflected in sell-side expectations should drive ACRS shares higher. We believe upwards consensus earnings revisions could come from: 1) Faster than expected uptake and higher than expected peak sales of A-101 for SK; 2) Commercialization of A-101 for common warts; and, 3) Free call options on ATI-50001, ATI-50002, and other early stage pipeline opportunities." (3/15/2017)

Who are some of Aclaris Therapeutics' key competitors?

Who owns Aclaris Therapeutics stock?

Aclaris Therapeutics' stock is owned by a variety of of institutional and retail investors. Top institutional investors include FMR LLC (0.00%), Sofinnova Management VIII L.L.C. (5.90%), Perceptive Advisors LLC (4.83%), Vanguard Group Inc. (0.00%), MARSHALL WACE ASIA Ltd (0.00%) and Marshall Wace North America L.P. (0.00%). Company insiders that own Aclaris Therapeutics stock include Albert Cha, Anand Mehra, Fmr Llc, Kamil Ali-Jackson, Ra Capital Management, Llc, Sofinnova Venture Partners Vii, Ventures Fund Vii LP Vivo and Vivo Ventures Vii, Llc. View Institutional Ownership Trends for Aclaris Therapeutics.

Who sold Aclaris Therapeutics stock? Who is selling Aclaris Therapeutics stock?

Aclaris Therapeutics' stock was sold by a variety of institutional investors in the last quarter, including Sofinnova Management VIII L.L.C., FIL Ltd, Driehaus Capital Management LLC, Renaissance Technologies LLC, Monashee Investment Management LLC, Eventide Asset Management LLC, Granite Point Capital Management L.P. and Morgan Stanley. Company insiders that have sold Aclaris Therapeutics stock in the last year include Anand Mehra, Kamil Ali-Jackson, Ra Capital Management, Llc and Ventures Fund Vii LP Vivo. View Insider Buying and Selling for Aclaris Therapeutics.

Who bought Aclaris Therapeutics stock? Who is buying Aclaris Therapeutics stock?

Aclaris Therapeutics' stock was bought by a variety of institutional investors in the last quarter, including FMR LLC, MARSHALL WACE ASIA Ltd, Marshall Wace North America L.P., Point72 Asset Management L.P., Loomis Sayles & Co. L P, EcoR1 Capital LLC, Westfield Capital Management Co. LP and Nexthera Capital LP. Company insiders that have bought Aclaris Therapeutics stock in the last two years include Albert Cha, Fmr Llc, Ra Capital Management, Llc, Sofinnova Venture Partners Vii and Vivo Ventures Vii, Llc. View Insider Buying and Selling for Aclaris Therapeutics.

How do I buy Aclaris Therapeutics stock?

Shares of Aclaris Therapeutics can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

How much does a share of Aclaris Therapeutics stock cost?

One share of Aclaris Therapeutics stock can currently be purchased for approximately $24.81.

Analyst Ratings

Consensus Ratings for Aclaris Therapeutics (NASDAQ:ACRS) (?)
Ratings Breakdown: 4 Buy Ratings
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $36.67 (47.79% upside)

Analysts' Ratings History for Aclaris Therapeutics (NASDAQ:ACRS)
Show:
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
5/25/2017Jefferies Group LLCReiterated RatingBuy$36.00MediumView Rating Details
4/6/2017GuggenheimReiterated RatingBuy$40.00HighView Rating Details
11/29/2016Leerink SwannInitiated CoverageOutperformN/AView Rating Details
9/30/2016JMP SecuritiesInitiated CoverageOutperform$34.00N/AView Rating Details
3/16/2016Citigroup IncLower Price TargetBuy$34.00 -> $29.00N/AView Rating Details
11/2/2015William BlairInitiated CoverageOutperform$30.00N/AView Rating Details
(Data available from 5/27/2015 forward)

Earnings

Earnings History for Aclaris Therapeutics (NASDAQ:ACRS)
Earnings by Quarter for Aclaris Therapeutics (NASDAQ:ACRS)
Earnings History by Quarter for Aclaris Therapeutics (NASDAQ:ACRS)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
5/9/2017Q1 2017($0.54)($0.48)ViewListenView Earnings Details
3/15/2017Q4 2016($0.59)($0.49)ViewN/AView Earnings Details
11/3/2016Q3($0.68)($0.50)ViewListenView Earnings Details
8/11/2016Q2($0.61)($0.62)ViewListenView Earnings Details
5/11/2016Q1($0.50)($0.65)ViewListenView Earnings Details
3/23/2016Q4($0.40)($0.28)ViewListenView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Aclaris Therapeutics (NASDAQ:ACRS)
2017 EPS Consensus Estimate: ($3.26)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20173($0.61)($0.45)($0.54)
Q2 20173($0.71)($0.64)($0.68)
Q3 20173($0.97)($0.81)($0.91)
Q4 20173($1.18)($1.05)($1.12)
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Aclaris Therapeutics (NASDAQ:ACRS)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading and Institutional Ownership History for Aclaris Therapeutics (NASDAQ:ACRS)
Insider Ownership Percentage: 46.40%
Institutional Ownership Percentage: 61.94%
Insider Trades by Quarter for Aclaris Therapeutics (NASDAQ:ACRS)
Institutional Ownership by Quarter for Aclaris Therapeutics (NASDAQ:ACRS)
Insider Trades by Quarter for Aclaris Therapeutics (NASDAQ:ACRS)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
3/2/2017Ventures Fund Vii L.P. VivoMajor ShareholderSell425,000$30.82$13,098,500.00View SEC Filing  
1/10/2017Anand MehraDirectorSell750,000$28.25$21,187,500.00View SEC Filing  
11/18/2016Ventures Fund Vii L.P. VivoMajor ShareholderSell907,828$23.03$20,907,278.84View SEC Filing  
10/26/2016Kamil Ali-JacksonInsiderSell3,912$21.83$85,398.96View SEC Filing  
9/28/2016Kamil Ali-JacksonInsiderSell1,841$24.66$45,399.06View SEC Filing  
9/16/2016Ra Capital Management, LlcMajor ShareholderSell525,550$24.19$12,713,054.50View SEC Filing  
8/26/2016Kamil Ali-JacksonInsiderSell3,738$20.35$76,068.30View SEC Filing  
2/23/2016Ra Capital Management, LlcMajor ShareholderBuy39,726$17.15$681,300.90View SEC Filing  
1/20/2016Ra Capital Management, LlcMajor ShareholderBuy7,803$19.87$155,045.61View SEC Filing  
1/13/2016Ra Capital Management, LlcMajor ShareholderBuy15,637$19.10$298,666.70View SEC Filing  
10/29/2015Ra Capital Management, LlcMajor ShareholderBuy244,200$14.00$3,418,800.00View SEC Filing  
10/22/2015Ra Capital Management, LlcMajor ShareholderBuy5,410$14.03$75,902.30View SEC Filing  
10/21/2015Ra Capital Management, LlcMajor ShareholderBuy34,999$14.89$521,135.11View SEC Filing  
10/14/2015Ra Capital Management, LlcMajor ShareholderBuy42,813$14.06$601,950.78View SEC Filing  
10/13/2015Albert ChaDirectorBuy454,545$11.00$4,999,995.00View SEC Filing  
10/13/2015Fmr LlcInsiderBuy335,455$11.00$3,690,005.00View SEC Filing  
10/13/2015Sofinnova Venture Partners ViiMajor ShareholderBuy409,090$11.00$4,499,990.00View SEC Filing  
10/8/2015Ra Capital Management, LlcMajor ShareholderBuy2,237,130$10.86$24,295,231.80View SEC Filing  
10/7/2015Vivo Ventures Vii, LlcMajor ShareholderBuy13,352$11.00$146,872.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Headline Trends for Aclaris Therapeutics (NASDAQ:ACRS)
Latest Headlines for Aclaris Therapeutics (NASDAQ:ACRS)
Source:
DateHeadline
americanbankingnews.com logoAclaris Therapeutics Inc (ACRS) Stock Rating Reaffirmed by Jefferies Group LLC
www.americanbankingnews.com - May 27 at 10:56 AM
americanbankingnews.com logoZacks Investment Research Lowers Aclaris Therapeutics Inc (ACRS) to Sell
www.americanbankingnews.com - May 12 at 4:40 PM
americanbankingnews.com logoJefferies Group Weighs in on Aclaris Therapeutics Inc's Q2 2017 Earnings (ACRS)
www.americanbankingnews.com - May 12 at 10:58 AM
americanbankingnews.com logoQ2 2017 EPS Estimates for Aclaris Therapeutics Inc (ACRS) Reduced by Leerink Swann
www.americanbankingnews.com - May 12 at 10:58 AM
americanbankingnews.com logoAclaris Therapeutics Inc to Post Q2 2017 Earnings of ($0.70) Per Share, William Blair Forecasts (ACRS)
www.americanbankingnews.com - May 12 at 10:42 AM
americanbankingnews.com logoEquities Analysts Offer Predictions for Aclaris Therapeutics Inc's FY2021 Earnings (ACRS)
www.americanbankingnews.com - May 11 at 3:58 PM
americanbankingnews.com logoBrokers Offer Predictions for Aclaris Therapeutics Inc's FY2020 Earnings (ACRS)
www.americanbankingnews.com - May 11 at 3:40 PM
americanbankingnews.com logoAclaris Therapeutics Inc (ACRS) Posts Earnings Results, Beats Expectations By $0.06 EPS
www.americanbankingnews.com - May 10 at 9:14 PM
finance.yahoo.com logoFDA Accepts Aclaris Therapeutics’ New Drug Application for Topical Treatment of Seborrheic Keratosis, a Common Skin Condition
finance.yahoo.com - May 10 at 9:34 AM
globenewswire.com logoAclaris Therapeutics Reports First Quarter 2017 Financial Results
globenewswire.com - May 9 at 8:20 PM
finance.yahoo.com logoAclaris reports 1Q loss
finance.yahoo.com - May 9 at 8:20 PM
finance.yahoo.com logoInvestor Network: Aclaris Therapeutics, Inc. to Host Earnings Call
finance.yahoo.com - May 9 at 3:19 PM
americanbankingnews.com logoAclaris Therapeutics Inc (ACRS) Scheduled to Post Quarterly Earnings on Tuesday
www.americanbankingnews.com - May 7 at 7:02 AM
americanbankingnews.com logo Analysts Expect Aclaris Therapeutics Inc (ACRS) Will Announce Earnings of -$0.54 Per Share
www.americanbankingnews.com - May 6 at 12:07 AM
streetinsider.com logoAclaris Therapeutics (ACRS) Completes Phase 1 Trial of ATI-50001 to Treat Alopecia Universalis and Alopecia Totalis
www.streetinsider.com - May 5 at 8:20 PM
finance.yahoo.com logoAclaris Therapeutics Completes Phase 1 Clinical Trial of ATI-50001 for the Treatment of Alopecia Universalis and Alopecia Totalis
finance.yahoo.com - May 5 at 3:19 PM
americanbankingnews.com logoAclaris Therapeutics (ACRS) Receives Coverage Optimism Score of 0.31
www.americanbankingnews.com - May 4 at 7:54 AM
finance.yahoo.com logoAclaris Therapeutics to Announce First Quarter 2017 Financial Results on May 9, 2017
finance.yahoo.com - May 2 at 5:52 AM
americanbankingnews.com logoAclaris Therapeutics (ACRS) Earning Somewhat Critical News Coverage, AlphaOne Reports
www.americanbankingnews.com - April 30 at 11:17 AM
americanbankingnews.com logoAclaris Therapeutics Inc (ACRS) Expected to Post FY2019 Earnings of ($1.71) Per Share
www.americanbankingnews.com - April 29 at 12:20 AM
americanbankingnews.com logoAclaris Therapeutics (ACRS) Receiving Positive Media Coverage, Analysis Shows
www.americanbankingnews.com - April 27 at 9:32 AM
finance.yahoo.com logoAclaris Therapeutics Announces Notice of Allowance for a U.S. Patent Application Covering Lead Candidate A-101 Topical Solution
finance.yahoo.com - April 26 at 3:27 PM
americanbankingnews.com logoAclaris Therapeutics (ACRS) Given Coverage Optimism Rating of 0.17
www.americanbankingnews.com - April 24 at 11:47 AM
americanbankingnews.com logoJefferies Group LLC Analysts Give Aclaris Therapeutics Inc (ACRS) a $36.00 Price Target
www.americanbankingnews.com - April 21 at 4:23 PM
americanbankingnews.com logoAclaris Therapeutics (ACRS) Earning Favorable News Coverage, Analysis Finds
www.americanbankingnews.com - April 21 at 8:17 AM
americanbankingnews.com logoAclaris Therapeutics (ACRS) Receives Media Sentiment Rating of -0.12
www.americanbankingnews.com - April 16 at 7:28 AM
americanbankingnews.com logoAclaris Therapeutics Inc (ACRS) Expected to Post Earnings of -$0.54 Per Share
www.americanbankingnews.com - April 15 at 12:06 AM
americanbankingnews.com logoAclaris Therapeutics (ACRS) Receiving Positive Press Coverage, Study Shows
www.americanbankingnews.com - April 13 at 11:35 AM
finance.yahoo.com logoAclaris Therapeutics Announces Notice of Allowance for Two U.S. Patent Applications Covering Baricitnib and Decernotinib, Respectively, for Hair Loss Disorders
finance.yahoo.com - April 7 at 6:01 AM
americanbankingnews.com logoAclaris Therapeutics' (ACRS) Buy Rating Reaffirmed at Guggenheim
www.americanbankingnews.com - April 6 at 9:31 AM
americanbankingnews.com logoAclaris Therapeutics Inc (ACRS) Short Interest Update
www.americanbankingnews.com - April 4 at 3:45 PM
americanbankingnews.com logoAclaris Therapeutics Inc (ACRS) Given a $36.00 Price Target at Jefferies Group LLC
www.americanbankingnews.com - March 22 at 8:20 AM
americanbankingnews.com logoGuggenheim Increases Aclaris Therapeutics Inc (ACRS) Price Target to $40.00
www.americanbankingnews.com - March 21 at 7:43 AM
americanbankingnews.com logoQ1 2017 EPS Estimates for Aclaris Therapeutics Inc Boosted by Analyst (ACRS)
www.americanbankingnews.com - March 20 at 9:55 AM
americanbankingnews.com logoAnalysts Offer Predictions for Aclaris Therapeutics Inc’s Q1 2017 Earnings (ACRS)
www.americanbankingnews.com - March 17 at 11:19 AM
americanbankingnews.com logoAclaris Therapeutics Inc (ACRS) Announces Quarterly Earnings Results, Beats Estimates By $0.10 EPS
www.americanbankingnews.com - March 16 at 10:43 AM
finance.yahoo.com logoEdited Transcript of ACRS earnings conference call or presentation 15-Mar-17 12:00pm GMT
finance.yahoo.com - March 15 at 8:24 PM
us.rd.yahoo.com logoAclaris Therapeutics Reports Fourth Quarter and Full Year 2016 Financial Results and Provides Corporate Update
us.rd.yahoo.com - March 15 at 3:23 PM
biz.yahoo.com logoQ4 2016 Aclaris Therapeutics Inc Earnings Release - Before Market Open
us.rd.yahoo.com - March 15 at 3:23 PM
biz.yahoo.com logoACLARIS THERAPEUTICS, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements an
us.rd.yahoo.com - March 15 at 3:23 PM
zacks.com logoHumana (HUM) Includes Methodist Healthcare in its Network
www.zacks.com - March 1 at 8:29 AM
streetinsider.com logoAclaris Therapeutics (ACRS) Submits NDA for A-101 as Novel Treatment for Seborrheic Keratosis
www.streetinsider.com - February 27 at 3:28 PM
finance.yahoo.com logoAclaris Therapeutics Submits New Drug Application for A-101 as a Novel Treatment for Seborrheic Keratosis – a Common Skin Condition
finance.yahoo.com - February 27 at 3:28 PM
finance.yahoo.com logo8:01 am Aclaris Therapeutics submits a NDA to the FDA for A-101 40% topical solution as a treatment for seborrheic keratosis; also plans to submit a MAA in the EU in mid-2017
finance.yahoo.com - February 27 at 3:28 PM
finance.yahoo.com logoAclaris Therapeutics (ACRS) Worth a Look: Stock Rises 8.5%
finance.yahoo.com - February 24 at 9:32 AM
finance.yahoo.com logoAclaris Therapeutics to Announce Fourth Quarter and Full Year 2016 Financial Results on March 15, 2017
finance.yahoo.com - February 23 at 3:19 PM
thestreet.com logoSkin Lesion Drug Only Scratches the Surface, Says Aclaris CEO
www.thestreet.com - February 6 at 3:22 PM
nasdaq.com logoNoteworthy Thursday Option Activity: P, ACRS, EW
www.nasdaq.com - February 2 at 8:21 PM
finance.yahoo.com logoAclaris Therapeutics Announces Appointment of Andrew Powell to Board of Directors
finance.yahoo.com - January 26 at 3:33 PM
biz.yahoo.com logoACLARIS THERAPEUTICS, INC. Files SEC form 8-K, Change in Directors or Principal Officers, Regulation FD Disclosure
biz.yahoo.com - January 26 at 3:33 PM

Social

Chart

Aclaris Therapeutics (ACRS) Chart for Saturday, May, 27, 2017

This page was last updated on 5/27/2017 by MarketBeat.com Staff